Westdeutsche Studiengruppe

Westdeutsche Studiengruppe (WSG) is a leading German academic research organization (ARO) focused on the optimization of breast cancer therapy through clinical trials. Founded in 1992, the group specializes in the design, coordination, and analysis of multicenter trials with a strong emphasis on personalized medicine and biomarker-guided treatment de-escalation. WSG is internationally recognized for its landmark trials, such as the PlanB and ADAPT series, which have helped define the role of gene expression assays in clinical practice. The organization operates a network of over 400 participating centers across Germany, providing a robust infrastructure for high-quality clinical research. By integrating translational research with clinical practice, WSG aims to improve patient outcomes while minimizing unnecessary treatment toxicity.